Swiss National Bank - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 194 filers reported holding SAGE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.

Quarter-by-quarter ownership
Swiss National Bank ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,432,556
-55.8%
118,200
+1.0%
0.00%
-50.0%
Q2 2023$5,501,340
+13.5%
117,000
+1.3%
0.00%
+33.3%
Q1 2023$4,846,380
-1.7%
115,500
-10.6%
0.00%
-25.0%
Q4 2022$4,927,688
-0.2%
129,200
+2.5%
0.00%0.0%
Q3 2022$4,938,000
+22.0%
126,100
+0.6%
0.00%
+33.3%
Q2 2022$4,047,000
-2.4%
125,3000.0%0.00%
+50.0%
Q1 2022$4,147,000
-16.2%
125,300
+7.7%
0.00%
-33.3%
Q4 2021$4,947,000
-4.0%
116,3000.0%0.00%0.0%
Q3 2021$5,153,000
-21.7%
116,300
+0.4%
0.00%
-25.0%
Q2 2021$6,579,000
-26.1%
115,800
-2.7%
0.00%
-33.3%
Q1 2021$8,907,000
-12.4%
119,000
+1.3%
0.01%
-14.3%
Q4 2020$10,165,000
+41.3%
117,500
-0.2%
0.01%
+16.7%
Q3 2020$7,194,000
+49.4%
117,700
+1.6%
0.01%
+50.0%
Q2 2020$4,815,000
+66.8%
115,800
+15.2%
0.00%
+33.3%
Q1 2020$2,886,000
-59.5%
100,500
+1.7%
0.00%
-57.1%
Q4 2019$7,132,000
-47.2%
98,800
+2.6%
0.01%
-50.0%
Q3 2019$13,510,000
-22.2%
96,300
+1.6%
0.01%
-26.3%
Q2 2019$17,357,000
+27.8%
94,800
+11.0%
0.02%
+26.7%
Q1 2019$13,583,000
+71.9%
85,400
+3.5%
0.02%
+50.0%
Q4 2018$7,903,000
-31.0%
82,500
+1.7%
0.01%
-23.1%
Q3 2018$11,455,000
-8.6%
81,100
+1.2%
0.01%
-7.1%
Q2 2018$12,538,000
-2.0%
80,100
+0.9%
0.01%
-12.5%
Q1 2018$12,789,000
+17.1%
79,400
+19.8%
0.02%
+33.3%
Q4 2017$10,920,000
+228.8%
66,300
+24.4%
0.01%
+200.0%
Q3 2017$3,321,000
-21.8%
53,3000.0%0.00%
-20.0%
Q2 2017$4,245,000
+14.6%
53,300
+2.3%
0.01%0.0%
Q1 2017$3,703,000
+43.6%
52,100
+3.2%
0.01%
+25.0%
Q4 2016$2,579,000
+10.9%
50,5000.0%0.00%0.0%
Q3 2016$2,326,000
+89.7%
50,500
+24.1%
0.00%
+100.0%
Q2 2016$1,226,000
+19.7%
40,700
+23.0%
0.00%0.0%
Q1 2016$1,024,000
+0.4%
33,100
+89.1%
0.00%0.0%
Q4 2015$1,020,000
+37.7%
17,5000.0%0.00%0.0%
Q3 2015$741,000
-32.3%
17,500
+16.7%
0.00%
-33.3%
Q2 2015$1,095,000
+296.7%
15,000
+172.7%
0.00%
+200.0%
Q1 2015$276,000
+37.3%
5,5000.0%0.00%0.0%
Q4 2014$201,0005,5000.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Integral Health Asset Management, LLC 311,000$10,294,0002.68%
Palo Alto Investors LP 851,719$28,192,0002.18%
Boxer Capital, LLC 1,094,000$36,211,0001.86%
DAFNA Capital Management LLC 180,306$5,968,0001.56%
Deep Track Capital, LP 675,000$22,343,0001.43%
Bellevue Group AG 3,052,404$101,034,0001.17%
Ikarian Capital, LLC 249,907$8,272,0001.09%
Ikarian Capital, LLC 250,000$8,275,0001.09%
Artal Group S.A. 750,000$24,825,0001.04%
SECTOR GAMMA AS 118,476$3,922,0000.85%
View complete list of SAGE THERAPEUTICS INC shareholders